We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
L'equip de Fisiopatologia Renal del VHIR
"Patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis present miRNA profiles in urinary extracellular vesicles associated with disease progression" was the awarded work.
A study conducted by the Renal Pathophysiology Research Group from the Vall d'Hebron Research Institute (VHIR), together with the Pediatric Nephrology Service from Vall d'Hebron University Hospital, was recently awarded at the 47th edition of the AENP Congress held in Bilbao. The AENP is a scientific association with more than 50 years of experience that promotes the development of paediatric nephrology in Spain, in educational, healthcare, clinical, and research fields, fostering relationships with other national and international associations.
The awarded presentation was "Patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis present miRNA profiles in urinary extracellular vesicles associated with disease progression". This study aims to identify the mechanisms of disease progression in Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC) and to understand why patients show different phenotypes that include rapid versus slow renal function loss with or without ocular involvement, despite having the same mutation (pG20D) in the Claudin 19 gene. It is an ultra-rare hereditary disease characterized by renal loss of calcium and magnesium, which can lead to end-stage renal failure requiring kidney transplantation within a few months of life in severe cases, and for which there is no specific treatment.
The research team isolated extracellular vesicles from the urine of patients with FHHNC to compare differential miRNA expression profiles between patients and healthy individuals, and between patients with different disease progression. The association of specific miRNAs with the disease and its progression has allowed the identification of possible non-invasive urinary biomarkers of clinical relevance and the proposal of potential therapies through the modulation of these miRNAs' expression. Additionally, this study has partially enabled us to understand the molecular mechanisms of disease progression and to define potential therapeutic targets and solutions using artificial intelligence algorithms.
This project has been made possible thanks to the participation of the Association for Information and Research on Familial Hypomagnesemia (HIPOFAM).
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.